PRME (Prime Medicine) EBITDA Margin %: -5,700.70% (As of Mar. 2026)


PRME Prime Medicine Inc PRME
25 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Prime Medicine EBITDA Margin %?

Prime Medicine PRME +2.09% 25 EBITDA Margin % is -5,700.70% as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Prime Medicine ranks worse than 90.04% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Prime Medicine's EBITDA for the three months ended in Mar. 2026 was $-48.80 Mil. Prime Medicine's Revenue for the three months ended in Mar. 2026 was $0.86 Mil. Therefore, Prime Medicine's EBITDA margin for the quarter that ended in Mar. 2026 was -5,700.70%.

Prime Medicine  (NAS:PRME) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Prime Medicine EBITDA Margin % Related Terms

Prime Medicine EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Prime Medicine's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine EBITDA Margin % Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -6,581.93 -4,340.00

Prime Medicine Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,486.38 -4,620.00 -4,252.41 -5,576.61 -5,700.70

PRME vs IMMX, SGP, ACRS: EBITDA Margin % Comparison

For the Biotechnology subindustry, Prime Medicine's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prime Medicine EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Prime Medicine's EBITDA Margin % falls into.


PRME
25GF Score
Prime Medicine Inc PRME
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prime Medicine EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Prime Medicine's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-201.029/4.632
=-4,340.00 %

Prime Medicine's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-48.798/0.856
=-5,700.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -5,700.70% mean?
Prime Medicine (PRME) has a EBITDA Margin % of -5,700.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #850 out of 944 companies in the Biotechnology industry, placing it in the top 90%.
Is Prime Medicine's EBITDA Margin % too high?
Prime Medicine's current EBITDA Margin % is -5,700.70%. Based on the distribution chart, Prime Medicine ranks #850 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's EBITDA Margin % compare to IMMX and SGP?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #850 out of 944 companies for EBITDA Margin %. This places Prime Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prime Medicine and its competitors. Prime Medicine's current EBITDA Margin % is -5,700.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current EBITDA Margin % of -5,700.70%. The current EBITDA Margin % is -5,700.70%. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Prime Medicine (PRME), the current EBITDA Margin % is -5,700.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score

Get the complete analysis for PRME

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price